SUN GLOBAL
SUN GLOBAL
Factory direct peptide supply
GLP-1 Receptor Agonist
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated significant efficacy in metabolic research. It works by mimicking the GLP-1 hormone, which stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. Our pharmaceutical-grade semaglutide is produced via solid-phase peptide synthesis (SPPS) with rigorous quality control at every stage.
For faster quotation, include purity, quantity, packaging request and target market.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated significant efficacy in metabolic research. It works by mimicking the GLP-1 hormone, which stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. Our pharmaceutical-grade semaglutide is produced via solid-phase peptide synthesis (SPPS) with rigorous quality control at every stage.
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH₂
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH₂
Batch-specific testing results
Factory supply workflow
Send the product name, selected strength, quantity, purity requirement, packaging style and destination market. The sales team can confirm stock, MOQ, batch COA, HPLC/MS files, lead time and private label options.
Product name, mg/vial, vial count and target quantity.
Batch COA, HPLC, MS, appearance and storage conditions.
Factory price, MOQ, label, box and custom brand support.
Fast preparation with export support and shipment updates.
Peer-reviewed scientific literature on Semaglutide from PubMed, NEJM, The Lancet, and other authoritative sources.
Wilding JPH, Batterham RL, Calanna S, et al.
New England Journal of Medicine, 384: 989–1002 (2021)
Participants receiving semaglutide lost a mean of 14.9% of body weight vs. 2.4% with placebo (p<0.001). 86.4% of semaglutide participants achieved ≥5% weight loss.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
New England Journal of Medicine, 389: 2221–2232 (2023)
Semaglutide reduced the risk of major adverse cardiovascular events by 20% (HR 0.80; 95% CI 0.72–0.90; p<0.001) compared to placebo over a mean follow-up of 39.8 months.
Ryan DH, Lingvay I, Colhoun HM, et al.
Obesity, 28: 1050–1061 (2020)
The STEP program demonstrated consistent and clinically reported metabolic outcomes across diverse research populations
